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RESUMO 
 
Na última década, estudos sobre a fisiopatologia da Hipertensão Arterial Pulmonar (HAP) demonstraram o 
papel crucial da remodelagem vascular, observando-se uma mudança do interesse da comunidade 
científica para a pesquisa de terapias anti-remodelagem. A remodelagem vascular pulmonar pode refletir 
um desequilíbrio entre mitógenios e inibidores de crescimento, com consequente desregulação da 
apoptose e proliferação celular. A fase inicial da HAP é geralmente caraterizada por apoptose a nível 
endotelial enquanto que a fase tardia é caraterizada por resistência à apoptose a nível da intima e da 
média. Deste modo, os doentes com HAP em fases precoces beneficiariam de terapias anti-apoptóticas, 
enquanto que doentes em estadios avançados beneficiariam de estratégias pró-apoptóticas. Neste sentido, 
avaliar o estado apoptótico de doentes com HAP ajudaria a individualizar terapias. Desta forma, a presente 
dissertação teve como objetivo caraterizar a expressão das proteínas da via intrínseca da apoptose, 
survivina e Smac/DIABLO, durante as fases precoce e tardia da HAP induzida pela monocrotalina (MCT). 
Avaliamos também in vivo os efeitos de uma estratégia pró-apoptótica usando terameprocol (TMP), um 
antagonista da survivina, num modelo experimental de HAP induzido por MCT. Os resultados obtidos 
demonstram que o aumento da expressão de survivina e a diminuição de Smac/DIABLO, tanto a nível 
cardíaco como pulmonar, precedem as manifestações hemodinâmicas da HAP, sugerindo fortemente uma 
causa neurohumoral ao invés de uma dependente da carga. Verificamos ainda que o tratamento com TMP 
resultou na reversão dos parâmetros hemodinâmicos e histológicos nos animais com hipertensão 
pulmonar. Concluindo, os dados deste estudo sugerem que a modulação da apoptose pela via da survivina 
poderá ter um duplo efeito benéfico através da reversão da remodelagem vascular pulmonar e da 
hipertrofia cardíaca. 
 
Palavras-chave: Hipertensão Arterial Pulmonar; apoptose; survivina; Smac/DIABLO; terameprocol.  
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ABSTRACT 
 
Over the last decade, research on the pathophysiology of Pulmonary Arterial Hypertension (PAH) 
highlighted the crucial role of vascular remodeling in its pathophysiology, with a shift in the interest of 
scientific community to seek anti-remodeling therapies rather than new vasodilators. According to this 
recent paradigm, pulmonary vascular remodeling might reflect an imbalance between mitogens and growth 
inhibitors with a deregulation on apoptosis and cell proliferation. Early-stages of PAH are characterized by 
endothelial apoptosis and late-stages of PAH by apoptosis resistance in both intimal and medial layers. 
Therefore, patients in early-stages of PAH would benefit from anti-apoptotic therapies whereas patients in 
advanced stages might benefit from pro-apoptotic strategies. In this context, assessing the apoptosis status 
would help on individualizing therapies for PAH patients. The present work aimed to characterize the 
expression of intrinsic apoptotic pathway proteins survivin and Smac/DIABLO during early and late stages 
of monocrotaline (MCT)-induced PAH. We also evaluated the in vivo effect of a pro-apoptotic strategy using 
terameprocol (TMP), a survivin antagonist, in a MCT-induced model of PAH. Results demonstrate that 
survivin upregulation and Smac/DIABLO downregulation at cardiac and pulmonary levels preceded 
hemodynamic manifestations of PAH, strongly suggesting a neurohumoral cause rather than a load-
dependent one. We also verified that TMP treatment resulted in reversion of hemodynamic and histological 
parameters in pulmonary hypertensive rats. In conclusion, our data suggest that targeting survivin in PAH 
could have dual beneficial effects, by reversing pulmonary vascular remodeling as well as cardiac 
hypertrophy.  
 
Keywords: Pulmonary Arterial Hypertension; apoptosis; survivin; Smac/DIABLO; terameprocol.  
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1. Pulmonary arterial hypertension 
1.1. Definition 
Pulmonary arterial hypertension (PAH) is clinically defined as mean pulmonary arterial pressure (PAP) 
elevation above 25 mmHg at rest or above 30 mmHg with exercise with a mean pulmonary capillary wedge 
pressure of less than 15 mmHg1. PAH is also characterized by vascular growth and proliferation, leading to 
increased vascular resistance and right heart failure2. 
 
1.2. Classification 
In 1981 German physician and pathologist Ernest Van Romberg described a case of right heart failure (HF) 
without a reason for pulmonary arteriosclerosis1 but it was only in 1951 that Dresdale and colleagues3 first 
used the term primary pulmonary hypertension (PPH). An epidemic increase of pulmonary arterial 
hypertension (PAH), attributed to the excessive use of appetite suppressing drug aminorex fumerate, led to 
the first World Health Organization (WHO) symposim in 1973 in Geneva4, where PH was divided in two 
categories: PPH, a rare disease with unknown cause and secondary PH, when a disorder is due to known 
underlying cause and risk factors5. Since then, several conferences on PH have been held. The “Evian 
classification” (2nd WHO symposium, Evian, France) in 1998 attempted to classify PH according to its 
pathological, clinical and therapeutic features. Later in 2003, the 3rd WHO symposium was held in Venice, 
Italy, where the most notable difference was the replacement of PPH in favour of idiopathic pulmonary 
arterial hypertension (IPAH), familial PAH (when exists a family history of PAH) or associated PAH (when 
another cause is present such presence of human immunodeficiency virus)6. The most recent classification 
was achieved in 2008 at the 4rd WHO symposium (Dana Point, California) where familial PAH was replaced 
by heritable PAH and left heart disease was subdivided in systolic and diastolic dysfunction as well as 
valvular disease. More recently, in March 2013 the 5th WHO Symposium was realized in Nice (France) 
however the new guidelines have not been published yet. 
Currently, PH is clinically classified in: i) PAH; ii) pulmonary veno-occlusive disease (PVOD) and/or 
pulmonary capillary hemanglomatosis (PCH); iii) PH owing to left heart disease; iv) PH owing to lung 
diseases and/or hypoxia; v) chronic thromboembolic PH (CTEPH); vi) PH with unclear multifactorial 
mechanisms (Table 1).  
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Table 1. WHO classification of pulmonary hypertension, Dana Point, 2008 
Group I. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH 
1.2. Heritable 
1.2.1. BMPR2 
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with: 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1.4.6. Chronic haemolytic anemia 
1.5. Persistent pulmonary hypertension of the newborn 
Group I’. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary haemangiomatosis (PCH) 
Group II. Pulmonary hypertension owing to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease 
Group III. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disorder breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental abnormalities   
Group IV. Chronic thromboembolic pulmonary hypertension (CTEPH) 
Group V. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders (myeloproliferative disorders, splenectomy) 
5.2. Systemic disorders (sarcoidosis, pulmonary Langerhans cell histiocytosis) 
5.3. Metabolic disorders (glycogen storage disease, Gaucher fisease, thyroid disorders) 
5.4. Others (tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis) 
 
 
 
Besides de clinical classification, PH patients can also be classified according to their functional 
performance (Table 2.). This classification has been adopted from the New York Heart Association (NYHA) 
for left heart disease and together with clinical classification can be useful for diagnosis, prognosis and 
therapy of PH.  
 
 
 
 
 
 
 
BMPR2 – bone morphogenetic protein receptor-II; ALK1 – activin receptor-like kinase 1; HIV – human 
immunodeficiency virus 
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Table 2. Functional classification of pulmonary arterial hypertension (adapted
7
) 
Class I 
Patients with pulmonary hypertension without resulting in limitation of physical activity. 
Normal physical activity does not cause undue dyspnoea or fatigue, chest pain or near syncope. 
Class II 
Patients with pulmonary hypertension resulting in slight limitation of physical activity. 
Patients comfortable at rest, but normal physical activity causes undue dyspnoea or fatigue, chest pain or near 
syncope. 
Class III 
Patients with pulmonary hypertension resulting in marked limitation of physical activity. 
Patients comfortable at rest, but less than normal physical activity causes undue dyspnoea or fatigue, chest 
pain or near syncope. 
Class IV 
Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. 
These patient manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
 
1.3. Epidemiology 
The incidence and prevalence of PAH, respectively, are estimated at 2.4-7.6 cases per million per year and 
15-26 cases per million in large population studies8, 9. Young adults are the most affected being more than 
two thirds women10. This female predominance might be explained by the low survival rate of male fetuses 
with PPH11. However, it is hard to appraise the global prevalence because it depends on the method of 
diagnosis and the specific groups of population studied. The worldwide prevalence of PAH is likely greater 
than is recognized given the newer associations with dialysis12 and metabolic syndrome13 as well as with 
the developing world diseases that are risk factors for PAH such as HIV, schistosomiosis and sickle cell 
disease14. However, non-PAH are increasingly far more common.  
 
1.4. Pathophysiology 
The normal pulmonary circulation is a low-pressure, low-resistance and high-capacitance system 
(pulmonary vascular resistance being less than one-tenth of systemic vascular resistance) where arteries 
are compliant structures with few muscle fibers. PAH is characterized by excessive pulmonary 
vasoconstriction and vascular remodeling that commonly affects all vessel layers (intima, media and 
adventitia) rising pulmonary vascular resistance (PVR) and PAP ultimately increasing right ventricular 
afterload. The histological findings in PAH include intimal thickening, medial hypertrophy (MH), adventitial 
proliferation/fibrosis, arterial occlusion, thrombosis in situ and infiltration of inflammatory/progenitor cells15, 
16. In the later stage of the disease, the formation of a vessel “neointima” is characterized by augmented 
deposition of extracellular matrix and myofibroblasts. Moreover, located downstream from occluded 
arteries, plexiform lesions can predominate and express growth factors typically observed in 
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angiogenesis17. It is still unknown the exact processes that initiate the pathological changes observed in 
PAH however the interaction of predisposing conditions and exogenous stimuli may represent the causes. 
 
1.4.1. Genetics 
The study of genetic predisposition of PAH is of utmost importance for the understanding pathogenesis of 
this disease. Mutations in bone morphogenetic protein (BMP) receptor-2 (BMPR2) are present in more than 
70% of familial PAH and 10%-40% of IPAH leading to loss of Smad signalling and therefore to increased 
proliferation and decreased differentiation of pulmonary artery smooth muscle cells (PASMCs) 18-20. In spite 
of the autosomal dominant inheritance of BMPR2 gene mutations, this disease has a low penetrance since 
only approximately 20% of individuals carrying the mutation will develop PAH 20. 
More research is currently being performed to find possible epigenetic mechanisms that enhanced PAH 
susceptibility, namely single nucleotide polymorphisms (SNP). SNP variants, including KV1.5
21, transient 
receptor potential (Trp) channels22 and serotonin (5-HT) transporters23, may predispose to PAH. 
 
1.4.2. PAH as panvasculopathy  
Accompanied by the histological features previously described, PAH is currently viewed as a 
panvasculopathy (Figure 1). In PAH the vasodilator/vasoconstrictor ratio is decreased in the endothelium24-
26 whereas prothrombotic factors, such as tissue factor27, are increased. Apoptosis in early stages of PAH 
may generate apoptosis-resistant endothelial cells (ECs) that cross-talk with PASMCs through growth 
factors (e.g. transforming growth factor-β, TGF-β) leading to EC and fibroblast transdifferentiation and 
PASMCs proliferation28, eventually forming plexiform lesions29. Besides growth factors, several other 
phenomena drive PASMCs into excessive proliferation including: mitochondrial abnormalities29, increased 
expression/activity of platelet-derived growth factor (PDGF) receptor30 and serotonin receptor (SERT)31, 32, 
tyrosine kinase activation33 and decreased expression of voltage-gated O2-sensitive potassium channel, 
KV1.5
34. Moreover, metalloproteinase activation causes disruption of the adventitia which allows cell 
migration and generates mitogenic peptides35. Furthermore, adventitial fibroblasts show a hyperproliferative 
phenotype in PAH, displaying increased sensitivity to 5-HT36.  
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Several observations indicate that PAH shares a mitochondrial-metabolic abnormality with cancer, the 
“Warburg phenotype”, a shift in glucose metabolism from oxidative phosphorylation to glycolysis (despite 
adequate oxygen supply) that enhances proliferation and prevents apoptosis37. The downstream 
consequences of this mitochondrial-metabolic abnormality include mitochondrial hyperpolarization, reduced 
production of reactive oxygen species (ROS), normoxic-activation of hypoxia inducible factor-1α (HIF-1α), 
overexpression of pyruvate dehydrogenase kinase (PDK) and decreased expression KV1.5 channels
37. 
Other groups demonstrated that these mitochondrial abnormalities can be partially reverted by 
Dichloroacetate (DCA), a PDK inhibitor and KV1.5 channel opener. Indeed, DCA activates pyruvate 
dehydrogenase (PDH), increasing glucose oxidation, restoring mitochondrial membrane potential and 
reversing normoxic HIF-1α activation37. 
 
 
Figure 1. PAH as panvasculopathy. In PAH several alterations occur in the 3 layers (adventitia, media and intima) of pulmonary arteries. PAH: 
Pulmonary Arterial Hypertension; SMC: Smooth muscle cell; EC: Endothelial cell; TGF: Transforming Growth Factor; PDGF: Platelet-derived 
Growth Factor. 
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1.4.3. Inflammation  
Increasing attention is being focused on several inflammatory mechanisms that play a key role in 
experimental models of PAH and in human PAH. These include the presence of T and B cells monocytes, 
macrophages and dendritic cells in plexiform lesions38, 39, the detection of autoantibodies on ECs and 
fibroblasts40, raised cytokine and chemokine levels41 and the association of PAH with certain infections such 
as human herpes virus 8 (HHV-8)42 and HIV43. The nuclear factor of activated T cells (NFAT) is known for 
increasing the transcription of multiple inflammatory mediators such as interleukins (IL) and tumour necrosis 
factor-α (TNF-α)44. Activation of NFAT in PAH causes the downregulation of KV1.5
45 and regulates the 
transcription of several genes that control mitochondrial function46. Moreover, NFAT was also found to be 
activated in PASMCs isolated from patients with PAH and that inhibition of its predominant isoform, 
NFATc2, would contribute to attenuate monocrotaline(MCT)-induced PAH47. 
Finally, PAH is associated with latent viral infections (such as HIV and HHV-8) and schistosomiasis (SSc). 
Nonhuman primates infected with chimeric simian HIV-nef virus demonstrated lung vascular remodeling 
characteristic of PAH48. Moreover, the HIV-nef gene was also implicated in plexiform lesions in pulmonary 
arteries of HIV-infected patients with PAH49. SSc, a parasitic infection that causes inflammation and 
pulmonary vascular disease, has also been implicated in PAH. Infiltration of T and B cells together with 
increased levels of IL-6, CX3CL1 and RANTES have been reported in the pulmonary vascular lesions of 
PAH patients with SSc6. Additionally mice chronically infected with SSc presented extensive pulmonary 
vascular remodeling in the absence of PH and correlated with cytokine IL-13 levels50. 
 
1.4.4. Right ventricular hypertrophy 
One of the consequences of PVR increasing is right ventricular overload leading to right ventricular 
hypertrophy (RVH) and failure. According to the Laplace relationship an elevated intraluminal pressure 
leads to an increase in wall stress, unless the chamber wall thickness is increased or the internal radius of 
the chamber is reduced. To compensate the high pressure registered in PAH, the right ventricle (RV) 
adapts by increasing wall thickness and assuming a more rounded shape51. The increase in ventricular 
mass is due to myocyte hypertrophy, sarcolemmal and contractile protein synthesis, altered calcium 
homeostasis, a shift in gene expression and extracellular matrix remodelling52. Although is known that the 
best approach to reduce RVH is to treat the underlying pulmonary arterial alterations, recent data suggests 
that RV can be an independent target in experimental PAH53. For exemple, inhibition of phosphodiesterase 
5 (PDE5) (e.g. sildenafil) improved RV contractility53, without altering left ventricle (LV) function. 
In normal conditions the RV is capable of adjusting its substrate utilization from fatty acids to glucose. In 
RVH the myocardium is reliant on anaerobic glucose metabolism due to PDK activation and it has 
hibernating properties, demonstrating augmented glucose oxidation and contractility in response to DCA54. 
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Studies in MCT-induced PAH have demonstrated an upregulation of glucose transporter protein 4 
(GLUT4)55. 
Moreover alterations in neurohumoral signalling, formation of ROS as well as nitrogen species and 
exaggerated inflammatory responses can also lead to right heart failure51. Still, more research is needed on 
therapy agents with effects on both RV and pulmonary vasculature. 
 
1.5. Experimental models 
Even though animal models do not mimic all the characteristics of human pathology, they have allowed the 
study on several diseases and its therapeutics56. Until now, no animal model has been able to mimic all the 
biochemical and histopathological features of PAH57. MCT and hypoxia are the most frequently used animal 
models in the study of this disease56. Although MCT model has been used for over than 50 years, the 
molecular mechanisms underlying MCT-induced PAH have yet to be better clarified58. 
 
1.5.1. Monocrotaline model 
Derived from the seeds of Crotalaria spectabilis, monocrotaline (MCT) is a toxic pyrrolizidine alkaloid that 
can be administrated by intraperiotoneal (60 mg/Kg), subcutaneous (60 mg/Kg), or intravenous injection (1-
5 mg/Kg) inducing vascular injury after hepatic generation of its pyrrolic derivative by cytochrome P450 3 
A59. With a single injection of MCT rats develop PAH after approximately 3 weeks and die within 6-8 
weeks60, making this a very simple and thus technically appealing animal model available to a wide 
spectrum of investigators. Unfortunately, MCT represents a significant limitation for long-term survival 
studies because it can injury other organs like the liver61 and the kidney62. Another limitation is the different 
sensitivity that rat strains present to MCT63 which may be related to the pharmacokinetics of this molecule59. 
MCT primarily affects the pulmonary arterial bed because lungs are the first major vascular bed after the 
liver64. In fact, at the pulmonary level, the ECs are the first site of damage. After only 4h of MCT 
administration rats develop platelet thrombi in small arteries65 and within 4 days EC toxicity by increasing 
the number of swollen mitochondria and decreasing the proportion of microfilaments66, 67. Approximately 7 
days after MCT injection there is a peripheral extension of SMCs into small nonmuscularized PAs66 and an 
increase in oxygen consumption and cardiac index68. The medial hypertrophy of small PAs is described 12 
days post MCT injection accompanied by an increase in PAP. RVH is only present later in the disease68 
(~21 days after injection) together with increased RV systolic and diastolic pressures and ultimately RV 
failure69-71.  
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2. Apoptosis in PAH 
 
The pathogenesis of PAH is a complicated, multifactorial process. The current vasodilator therapies are 
limited and research is now pursing strategies that could reverse structural remodeling in the pulmonary 
arterial bed, thus providing a more significant decrease in PVR. Even though growth is the classical 
mechanism associated with vascular remodeling, it has increasingly been acceptable that apoptosis may 
influence the extent of alterations that occurs72. Indeed, a reduction in apoptosis has been implicated in 
severe PAH while induction of this mechanism seems to promote the regression of pulmonary vascular 
remodeling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Apoptosis pathways. Two major pathways are present during apoptosis: the extrinsic (or death receptor pathway) and the intrinsic (or 
mitochondrial pathway). In the extrinsic pathway the activation of death receptors leads to the formation of death inducing signalling complex 
(DISC) and activation of procaspase-8, initiating the caspase cascade. In the intrinsic pathway, the death stimuli leads to opening of the 
mitochondrial permeability transition pore (MPT) and thus to the release of cytochrome c and Smac/DIABLO. Cytochrome c will, together with 
Apaf-1 and procaspase-9, form the apoptossome and activate caspase cascade while Smac/DIABLO will suppress inhibitor of apoptosis proteins 
(IAPs) thus contributing to caspase activation and apoptosis. Finally the balance between pro and anti-apoptotic Bcl proteins will determine the 
mitochondrial response to death stimuli. FADD: Fas-associated death domain protein; TRADD: Tumor necrosis factor receptor type 1-associated 
death domain protein. 
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Apoptosis, or programmed cell death, is an important biological process of normal tissue development and 
function that involves the genetically determined elimination of cells. It is characterized by a distinct series 
of morphological and biochemical alterations such as cell shrinkage, chromatin condensation, DNA 
fragmentation, caspase activation, formation of apoptotic bodies and membrane blebbing73-75. The apoptotic 
events are initiated when the cells loss their volume upon the receiver of apoptotic signals (Figure 2). Then 
mitochondrial membrane potential is depolarized, cytochrome c (cyt c) is released and caspases are 
activated. Finally, the last phase is when the DNA degradation occurs, apoptotic bodies are formed, the 
nuclear lamina and cytoskeleton are degraded and the internal phosphatidyl serine is exposed to the 
external environment.  
Until now, two major apoptotic pathways are known: the intrinsic or mitochondrial pathway and the extrinsic 
or death receptor pathway. Both pathways converge on the same execution phase that involves the 
activation of specific cysteinyl aspartic acid-proteases (caspase-3, caspase-6 and caspase-7). These 
activate cytoplasmic endonucleases and proteases that degrade nuclear and cytoskeletal material76. The 
extrinsic pathway initiates apoptosis through transmembrane receptor-mediated interactions involving death 
receptors and ligands that are members of the TNF receptor gene superfamily77 like FasR/FasL, 
TNFR1/TNF-α/,  DR3/Apo3L/, DR4/Apo2L and DR5/Apo2L78-82. Upon ligand binding cytoplasmic adapter 
proteins, such as FADD and TRADD, are recruited and associated with procaspase-8 via dimerization of 
the death effector domain. This leads to the formation of a death-inducing signalling complex (DISC) that 
activates procaspase-883. After that, the execution phase begins with the activation of caspase-8. The 
intrinsic pathway can be initiated through either negative signalling (absence of factors that suppress death 
programs such as growth factors, hormones and cytokines) or positive signalling (radiation, toxins hypoxia, 
hyperthermia, viral infections and free radicals). Both signals lead to loss of the mitochondrial 
transmembrane potential, formation of the mitochondrial permeability transition pore (MPT) and release of 
pro-apoptotic proteins such as cytochrome c and Smac/DIABLO from the intermembrane space to the 
cytosol84. Once released into cytosol, cytochrome c binds and activates Apaf-1 and procaspase-9 to form 
the “apoptosome”85, 86 which then activates caspase-9 and lead to chromatin degradation and apoptosis. 
Although the exact mechanisms are yet to be discovered, thoughts are that Bcl-2 family of proteins is the 
responsible for the regulation of apoptotic mitochondrial events87. This family of proteins is constituted by 
either pro-apoptotic proteins (Bcl-10, Bax, Bak, Bid, Bad, Dim, Bik and Blk), that upon mitochondrial 
transmembrane potential depolarization regulate cytochrome c release88, and anti-apoptotic proteins (Bcl-2, 
Bcl-x, Bcl-XL, Bcl-XS, Bcl-w and BAG) that can promote mitochondrial hyperpolarization and prevent both 
the opening of MPT and release of cytochrome c89. 
In addition, ion channels are known to perform an essential role in apoptosis. High concentration of 
intracellular K+ ([K+]i) is needed to maintain a normal cell volume. Opening of plasma membrane voltage-
gated K+ channels increases the loss of cytoplasmic K+ inducing apoptotic volume decrease (AVD). On the 
other hand, closure or downregulation of K+ channels contributes to the maintenance of [K+]i attenuating 
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apoptosis90, 91. Moreover [K+]i is also required for the suppression of caspases and nucleases in the final 
apoptotic stage91. 
Finally, the last component of apoptosis is the phagocytic uptake of apoptotic bodies where the 
externalization of phosphotidylserine onto the outer leaflet facilitates noninflammatory phagocytic 
recognition leading to an early uptake and disposal92.  
 
2.1. The role of apoptosis in pulmonary vascular remodeling  
Recent research demonstrated that apoptosis has an important pathophysiological role in PAH by 
eliminating unwanted cells such as cells migrated into the vascular lumen and hypertrophied cells 
accumulated in the pulmonary vasculature93.  
Apoptotic modulators in the vasculature are diverse and include ROS94, NO95, angiotensin type 2 (AT2) 
receptors96 and the endothelin system97. For exemple, ROS are involved in PAH and more specifically in 
H2O2 induced-apoptosis of vascular cells by PKC dependent mechanism
98.  
Animal studies demonstrated that inducing apoptosis of hypertrophied PASMC in intact pulmonary 
vasculature can prevent the progression of the medial hypertrophy93, 99, 100.  
Moreover, apoptosis of hypertrophied PASMCs has been related to a regression in medial hypertrophy 
while inhibition of apoptosis is related to progression of pulmonary vascular medial thickening100-102. This 
assumption is based on the theory for a spatio-temporal diversity within the vascular wall as PAH 
progresses. In this theory, an inherited or acquired alteration in BMP axis promotes the apoptosis of 
pulmonary artery endothelial cells (PAECs) and consequently loss of small capillaries (constituted 
essentially by PAECs tubes) leading to the increase of the flow and shear stress in the remaining vessels. 
Intima cell proliferation and plexiform lesions are formed with the emergence of apoptosis-resistant PAECs 
expressing survivin29. Simultaneously, the loss of PAECs expose PASMCs to circulating growth factors 
such PDGF that has been shown to induce the expression of survivin103 and thus a resistance to apoptosis. 
Although all of this knowledge, the role of apoptosis in the pulmonary vascular remodeling needs further 
research. Studies on the mechanisms and biochemical markers of apoptosis will help in the understanding 
the role of apoptosis has a treatment for PAH. 
 
2.2. Apoptosis as therapeutic target for PAH 
Discover that normal vascular smooth muscle cells (VSMCs) possess the machinery to undergo apoptosis 
allowed the assumption that this phenomenon may be the one responsible for regulating cell number in the 
vessel wall.104 While early PAH is characterized by increased apoptosis in the endothelial layer, late 
disease is characterized by suppressed apoptosis and increased proliferation both in intima and media. 
Therefore an anti-remodeling treatment may be a potential therapeutic option against various types of PAH. 
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Patients in early stages of PAH may benefit from an antiapoptotic strategy, whereas the ones in late forms 
of PAH may receive a pro-apoptotic approach.  
 
2.2.1. Survivin 
Inhibitors of apoptosis (IAPs) are a family of proteins related with apoptosis. Several mammalian IAP family 
members have been identified including, NIAP105, c-IAP1 and 2, X-IAP106, apollon, TX-XIAP, livin , survivin 
and bruce. 107-109  
Survivin is a IAP known for its double function as inhibitor of apoptosis and regulator of cell division110 
(Figure 3.). This protein was first discovered in 1997 by Ambrosini and collegues while hibridization 
screening of a human genomic library with cDNA of the effector cell protease receptor-1 (EPR-1)111. 
Survivin presents a high homology to EPR-1 and has been mapped to chromosome 17 at band 25 
encoding a protein of 142 amino acids, with a molecular weight of approximately 16.3 kDa111. The initial 
studies revealed a strong survivin expression in fetal tissues whereas little or no survivin was detected in 
normal adult tissues110, 112-115. Interestingly, this protein is known to be expressed in most cancers and it is 
described as the fourth most significant transcriptome expressed in human tumors116. The feature that 
defines apoptosis in the IAP protein family members is the presence of baculovirus IAP repeat (BIR) in at 
least one copy. Inhibition of proteolytic maturation and enzyme activity of caspases by IAPs may be due to 
a physical association with initiator and effector caspases114, 117. In fact, several IAPs BIRs act as caspases-
interacting regions. The dual function that separates survivin from the other IAP family members is ensured 
by its unique structure. Sense this protein presents only one copy of a modified BIR domain similar to the 
three-dimensional structure BIR3 domain of XIAP. Survivin is thought to be able to interact with XIAP, 
protecting it from ubiquitination and increasing its stability leading to caspase-9 inhibition118, 119. This 
interaction was also studied through HeLa cells in which loss of phosphorylation of threonine 34 by p34cdc2-
cyclin B1 leads to dissociation of an immunoprecipitable survivin-caspase-9 complex on the mitotic 
apparatus and thus caspase-9-dependent apoptosis119. Moreover, expression of the T34A dominant-
negative mutant has shown a depletion of procaspase-9 in culture tumor cell lines120.  
Despite direct binding between survivin and the caspases has not been confirmed, survivin may also inhibit 
caspase activity indirectly through the mitochondrial pathway of apoptosis.  
Mitochondrial pro-apoptotic dimeric protein Smac/DIABLO is known for increasing Apo-2L/TRAIL-induced 
caspase-3 activity and thus suppress the activity of survivin and other IAPs such XIAP and cIAP1121. During 
mitochondrial apoptosis pathway Smac/DIABLO along with cytochrome c are released from mitochondria 
into the cytosol promoting apoptosis. This is due to the suppression of inhibitor effects of the IAP 
proteins122. Concluding, the binding of Smac/DIABLO to survivin leads to its delayed release in the cytosol, 
which in turn results in prolonged cell survival123.  
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Most IAP family members are considered anti-apoptotic proteins, however the gene that encodes survivin 
(BIRC5) generates five major isoforms of the transcript by alternative splicing: survivin-2α and survivin-2B 
that favour induction of apoptosis as well as survivin-ΔEx3, survivin-3B and wild type (WT)-survivin that 
appear to be cytoprotective124-126. Survivin is the only IAP protein capable of regulating cell division by 
interacting with the mitotic apparatus by binding to microtubules through its C-terminal domain127. In fact its 
expression is present on centromeres at prophase/metaphase and in the spindle midzone during 
anaphase/telophase128, 129. Survivin recognizes phosphorylated histone H3 associating with the 
chromosome passenger proteins Aurora B, INCENP and the neoformed complex is recruited to the 
centromeres to ensure a proper chromosomal segregation130. Moreover, survivin is present in 
centrossomes of dividing cells where it binds to Cdk1 which after activation allows cells to enter mitosis119.  
It has been proposed that survivin has multiple compartmentalizations in the cells that include the nucleus, 
the cytoplasm and the mitochondria118, 131, 132. Nuclear localization seems to be connected to the ability of 
survivin to regulate cell cycle by facilitating progression and inducing exit of the cells from G1 checkpoint 
Figure 3. Roles of survivin. Survivin is the only inhibitor of apoptosis protein (IAP) known for its double function in inhibiting apoptosis and 
regulating cell division. Survivin is capable of inhibiting caspases either directly or indirectly (in association with XIAP). Also Smac/DIABLO 
release suppresses survivin activity. In respect to cell cycle, survivin can be located in the mitotic spindle and the centromeres where in 
association with proteins Aurora B, Borealin and INCENP regulate chromosome segregation.  
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arrest and subsequent entry into S phase133-135. The greatest stability of survivin happens in the 
mitochondria where it is associated with oncogenic transformation, possibly increasing protection from 
apoptosis in cancer cells. This survivin confers resistance to apoptosis by inhibiting activation of effector 
caspases118, 132. Once apoptosis is initiated survivin exit the mitochondria and remains in cytoplasm where it 
loses its cytoprotective ability, probably because posttranslational modifications occur136. Finally, it was 
recently described that stress stimuli leads to a release of survivin to the cytosol, retaining both anti-
apoptotic and proliferative actions137-139. It is believe that the increased release of mitochondrial survivin to 
cytoplasm and sequestering of Smac/DIABLO are of the utmost importance for the apoptosis resistant 
phenotype of neoplasic cells. This findings lead to the thought that use of molecular antagonists of survivin 
to increase cell death and prevent pathological resistance to apoptosis might hold therapeutic potential. 
 
2.2.1.1. Terameprocol  
Terameprocol (tetra-O-methyl nordihydroguairetic acid, M4N, EM1421, TMP) is a hydrophobic molecule 
derivated of the nordihydroguairetic acid (NDGA) isolated from the plant Larrea tridentata140, 141, known for 
obliterating survivin gene expression142, 143 by binding to the transcription factor Sp1. In vitro studies 
demonstrate that terameprocol induced apoptosis and growth arrest of various human cancer cell lines142-
148. In vivo experiments with murine models of human xenograft solid tumors demonstrated the anti-tumoral 
action of this compound with no relevant systemic toxicity143-147. Moreover, clinical trials are already initiated 
to evaluate the potential of TMP in diverse types of neoplasias and also in the prevention of sexually 
transmitted viruses. 
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Considering the concepts reviewed before, the aim of the present study was to investigate the contribution 
of apoptosis to the pathogenesis of PAH through the analysis and modulation of the anti-apoptotic protein 
survivin in an animal model of MCT induced-PAH.  
In order to achieve the objective the work was divided in two parts, namely: 
a) Survivin expression in the progression of MCT-induced PAH 
 Pulmonary and cardiac patterns of controls and animals with MCT-induced PAH were 
related with expression of survivin and Smac/DIABLO proteins throughout the hemodynamic 
and morphometric progression of disease; 
b) Terameprocol in vivo study 
 The effects of terameprocol in vivo administration were characterized through morphometric 
and hemodynamic evaluation of sham and pulmonary hypertensive rats. 
 
 
  
 
 
 
 
 
Part III – Material and 
Methods 
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Figure 4. Experimental design. Progression of MCT-induced PAH and Terameprocol "in vivo" studies. MCT: Monocrotaline; PAH: Pulmonary 
arterial hypertension; sc: subcutaneous; DMSO: Dimethyl sulphoxide hybri-max; TMP: Terameprocol; ip: intraperitoneal. 
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3. Experimental Design 
Animal experiments were performed according to the Portuguese law for animal welfare and conform to the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, 
Revised 2011). Figure 4. represents the studies performed. 
 
3.1. Survivin expression in the progression of MCT-induced PAH 
Male Wistar Han rats (Charles River Laboratories, Barcelona, Spain) weighing 180-200 g were housed in 
groups of 5 animals/cage, in a controlled environment under a 12:12-h light-dark cycle at a room 
temperature of 22ºC, with free supply of food and water. Rats randomly received a subcutaneous injection 
of MCT (60 mg/kg, Sigma, Barcelona, Spain) (MCT groups, n=15/time point) or an equal volume of vehicle 
(1 mL/kg of 0.9% NaCl) (SHAM groups, n=10/time point). In order to evaluate the progression of the 
disease, hemodynamic assessment was performed on days 1, 3, 7, 14 or 21 after MCT/vehicle injection 
followed by sample collection. 
 
3.2. Terameprocol in vivo study 
Animals were randomly submitted to four different protocols: i) SHAM injected Dimethyl sulphoxide hybri-
max (DMSO, 1 mL/Kg, intraperitoneal (ip); Sigma, Barcelona, Spain) (Sham+Vehicle, n=10), ii) SHAM 
injected with tetra-O-methyl nordihydroguairetic acid (Terameprocol or TMP, 166 mg/Kg, ip; Cayman 
Chemical, Michigan, USA) (Sham+TMP, n=10) iii) MCT injected with DMSO (MCT+Vehicle, n=15) and iv) 
MCT injected with TMP (MCT+TMP, n=15). DMSO or TMP were administrated at day seven after MCT or 
vehicle injection, a time point where significant morphological and molecular alterations were already noted 
in the first study, and at every five days until hemodynamic evaluation (21 days after MCT or vehicle). 
 
4. Hemodynamic analysis 
Animals were anesthetized by inhalation of mixture of sevoflurane (4%) and oxygen, intubated for 
mechanical ventilation (Dual Mode, Kent Scientific, Connecticut, USA) and placed over a heating pad (body 
temperature was maintained at 37°C). Under binocular surgical microscopy (Wild M651.MS-D, Leica; 
Herbrugg, Switzerlad), the right jugular vein was cannulated for fluid administration (prewarmed 0.9% NaCl 
solution) to compensate for perioperative losses. The heart was exposed by a median sternotomy and the 
pericardium was widely opened. Bi-ventricular hemodynamic function was measured with pressure-volume 
(PV) catheters (PVR-1045 for RV and PVR-1035 for LV, Millar instruments, Houston, USA). Data was 
continually acquired (MPVS 300, Millar Instruments, Houston, USA) and digitally recorded at 1000Hz 
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(ML880 PowerLab 16/30, Millar TM instruments, Houston, USA). After complete instrumentation, the animal 
preparation was allowed to stabilize for 15 min. Hemodynamic recording was made under basal conditions 
and under vena cava, ascending aorta or pulmonary artery occlusion with respiration suspended at end-
expiration. Parallel conductance values were obtained by the injection of approximately 100 µl of 10% NaCl 
into the right atrium. Calibration from relative volume units (RVU) conductance signal to absolute volumes 
(µl) was undertaken using a previously validated method of comparison to known volumes in Perspex 
wells149. Heart rate (HR), RV and LV peak systolic pressure (Pmax), end-diastolic pressure (EDP), peak rate 
for pressure rise (dP/dtmax), peak rate of pressure decline (dP/dtmin), constant time of isovolumetric pressure 
decline (Tau), ejection fraction (EF), cardiac output (CO) and maximal elastance (Ea) were obtained and 
analysed using PVAN 3.5 and LabChart 7.0 (Millar Instruments, Houston, USA). 
 
5. Tissue Preparation 
The heart (H), lungs and right gastrocnemius muscle were excised and weighted. The right tibia was also 
excised and its length was measured with a millimetric ruler. Under binocular magnification (x3.5, Wild 
M651.MS-D, Leica; Herbrugg, Switzerlad), the RV free wall was dissected from the left ventricle + septum 
(S) and weighted separately. Heart, lungs, RV and LV+S weights were normalized to body weight (BW) and 
gastrocnemius weight was normalized to tibial length. Samples from heart and lung were fixed and included 
in paraffin for light microscopy, or frozen with liquid nitrogen for molecular studies. 
 
6. Morphometric analysis 
Samples of RV, LV (midway between the apex and base) and lung were fixed in 4% (v/v) buffered 
paraformaldehyde followed by dehydration with graded ethanol, diaphanization with xylene and included in 
paraffin blocks. Serial sections (4 µm of thickness) of paraffin blocks were cut by a microtome 
(RM2125RTS, Leica, Nussloch, Germany) and mounted on silane-coated slides. The slides were dewaxed 
in xylene, hydrated through graded alcohols and stained for haematoxylin-eosin by immersing slides in 
Mayer’s haematoxylin solution for 5 min. followed by immersion in aqueous eosin solution for 5 min. Slides 
were after submitted to graded alcohols and xylene and mounted with Entellan. Studied samples were 
observed at light microscopy (Dialux 20, Leitz, Wetzlar, Germany), photographed with a digital camera 
(XC30, Olympus, California, USA) and measured with a digital image analyzer (cell^B life science basic 
imaging software, Olympus, California, USA). Five images of random microscopic fields (magnification of 
x400) were obtained from each section to compensate for variations within sections. Only round to ovoid 
muscle fibers with a nuclear profile were counted to measure the cardiomyocytes surface area (CSA) being 
500 cardiomyocytes/group/time point analyzed. On pulmonary specimens, external diameter and medial 
wall thickness in muscular arteries (20-25 arteries/animal, 10 animals/group/time point) were analyzed. 
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Orthogonal intercepts were used to generate eight random measurements of external diameter (distance 
between the external lamina) and sixteen random measurements of medial thickness (distance between the 
internal and external lamina). For each artery medial hypertrophy was expressed as follows: % wall 
thickness = [(medial thickness x 2) / (external diameter)] x 100. 
 
7. Imunohistochemistry 
Imunohistochemistry was performed to determine survivin and Smac/DIABLO expression in the RV. 
Sections (4 µm) were placed on SuperFrost®Plus slides followed by deparaffinization, rehydration, and 
subjected to heat induced antigen retrieval by immersion in 10 mM sodium citrate buffer (C6H5Na3O7
.2H2O, 
pH 6.0) in the microwave for 30 min. Endogenous peroxidase activity was blocked by 3% hydrogen 
peroxide for 10 min. at room temperature (RT). Blockage of non-specific binding was performed with 5% 
normal goat serum (NGS) in TBS (100 mM Tris, 1.5 mM NaCl, pH 8.0) 0.1% Tween-20 (TBS-T) for 1 hour, 
RT flowed by 3 washes, 5 min. each in TBS-T. Sections were encircled with a pap pen (Vector 
Laboratories, California, USA) to prevent splitting leakage of the flowing incubation solutions. Endogenous 
avidin-biotin expression was blocked using an endogenous avidin + biotin blocking system, (ab3387, 
abcam, Cambridge, UK), according to manufacturer’s instructions, being followed by incubation with the 
primary antibodies (1:500 dilution; rabbit anti-survivin, ab469; dilution 1:250; rabbit anti-Smac/DIABLO, 
ab8115, abcam, Cambridge, UK) overnight at 4°C. After incubation with primary antibodies, slides were 
washed 3 times, 5 min each with TBS-T, RT and incubated with goat anti-rabbit IgG secondary antibody 
(1:250 dilution; ab6720, abcam, Cambridge, UK) for 2 hours, RT. Slides were submitted to another 3 
washes, 5min each in TBS-T, RT prior being incubated with streptavidin protein, HRP (1:1000 dilution; 
ab7403, abcam, Cambridge, UK). To visualize the peroxidase activity in sections 3,3-diaminobenzidine 
(DAB, ab94665, abcam, Cambridge, UK) was used. Finally, slides were counterstained with Mayer’s 
haematoxylin, submitted to graded alcohols and xylene and mounted with Entellan. Negative control 
reactions included omission of the primary antibody. The slides were observed and photographed with a 
microscope (Dialux 20, Leitz, Wetzlar, Germany) under x400 magnification. Survivin and Smac/DIABLO 
expression was qualitatively determined as positive (cytoplasmatic staining) or negative (500 
cardiomyocytes/group/time point). 
 
8. Western Blotting 
RV, LV and lung samples (n=6 animals/group/time point) previously frozen with liquid nitrogen were 
homogenised in phosphate buffer (13 mM KH2PO4, 54mM NaHPO4, pH 7.4) (in the proportion of 1:20) with 
a Bio-Gen PRO200 homogeniser (Pro 200, Pro Scientific, Connecticut, USA). Total protein concentration 
was spectrophotometrically determined with the colorimetric method RC-DC protein assay (Bio-Rad, 
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California, USA). The optic density was determined at 750nm in a microplate reader (UVM340, Asys, 
Cambridge, UK). Simultaneously, a calibration curve was performed using different concentrations of 
bovine serum albumin (BSA). 
Equivalent amounts of total protein from the homogenized RV, LV and lung of each group were 
electrophoresed on a 12.5% SDS-PAGE at 200V at room temperature as described by Laemmli150. Gels 
containing total proteins were transferred to a nitrocellulose membrane (0.2 µm, Bio-Rad, California, USA) 
in 25 mM Tris, 192 mM and 20% methanol at 200 mA. Equal loading of membranes was confirmed by 
staining the membranes with Ponceau S and nonspecific binding was blocked with 5 % (w/v) dry non-fat 
milk in TBS-T. Membranes were incubated with primary antibody (1:1000 dilution; rabbit anti-survivin, 
ab469; 1:500 dilution, rabbit anti-Smac/DIABLO, ab8115, abcam, Cambridge, UK) overnight at 4°C with 
agitation. Afterwards, blots were washed in TBS-T and incubated with a secondary antibody (1:15000, LI-
COR IRDye® 800CW, Nebraska, USA). Immunoreactive bands were observed under fluorescence using 
an Odyssey system (LI-COR Odyssey, Nebraska, USA) and the results were analyzed with Quantity One 
software v. 4.6.3 (Bio-Rad, California, USA). 
 
9. Statistical Analysis 
Statistical analysis was performed using Graph Pad Prism software (version 5.0, Graph Pad software, 
California, USA). All data are presented as mean ± SEM and were compared using Two Way ANOVA. 
When treatments were significantly different, Students-Newman Keuls post-hoc test was selected to 
perform pairwise multiple comparisons. Results were considered significantly different when p<0.05. 
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10. Progression of MCT-induced pulmonary arterial hypertension 
 
10.1. Right ventricle hemodynamic evaluation 
Table 4. represents the results from RV hemodynamic evaluation. RVPmax, dP/dtmax and dP/dtmin were 
significantly different between Sham and MCT groups 14 and 21 days after injection. Also, in MCT groups 
and at day 21, RVPmax was significantly augmented when compared with the previous time-points. MCT 
treatment did not induce any alterations in heart rate and end-diastolic pressure. 
 
10.2. Morphometric analysis 
Table 5. summarizes the morphometric progression of MCT-induced PAH. In Sham groups there is a 
significant increase in body weight throughout the protocol. In contrast, MCT animals had a lower weight 
gain being significantly different at day 21 after injection. No variation in the relation HT/BW was observed 
in MCT group, while it was reduced in the Sham group on days 14 and 21. MCT administration induced 
hypertrophy as expressed by the indexes RV/(LV+S) and RV/BW, both significantly increased on D21. Also, 
MCT-treated animals developed hypertrophy at cellular level represented by a significant increase in RV 
cardiomyocyte cross sectional area since day 7 after injection and progressively until day 21. Neither 
groups presented any changes in the left ventricle ((LV+S)/BW parameter). 
  
Table 3. Right ventricle hemodynamic evaluation parameters.  
 
D1 D3 D7 D14 D21 
 
Sham MCT Sham MCT Sham MCT Sham MCT Sham MCT 
Heart rate (bpm) 378 ± 23 413 ± 14 410 ± 18 387 ± 20 349 ± 22 357 ± 10 358 ± 35 385 ± 30 340 ± 14 376 ± 23 
Pmax(mmHg) 28.0 ± 1.9 28.3 ± 2.1 27.2 ± 0.8 28.2 ± 1.6 27.3 ± 2.2 31.5 ± 1.5 23.7 ± 1.0 31.9 ± 1.3 * 26.3 ± 1.2 38.9 ± 2.7 *
,a,b,c,d
 
EDP (mmHg) 3.9 ± 0.5 2.7 ± 0.3 3.2 ± 0.3 2.7 ± 0.3 3.9 ± 0.3 4.2 ± 1.0 3.9 ± 0.2 3.4 ± 0.7 3.6 ± 0.4 3.5 ± 0.3 
dP/dtmax (mmHg/sec) 1671 ± 152 1858 ± 184 1901 ± 90 2102 ± 217 1685 ± 155 1906 ± 83 1405 ± 101 2233 ± 190 * 1563 ± 60 2257 ± 65 * 
dP/dtmin (mmHg/sec) -1544 ± 355 -1421 ± 189 -1629 ± 109 -1702 ± 230 -1624 ± 204 -1441 ± 142 -1020 ± 144 -1830 ± 172 * -1228 ± 113 2263 ± 93 *
,b,c
 
 
 
Pmax: maximum pressure; EDP: end-diastolic pressure; dP/dtmax: peak rate of pressure rise; dP/dtmin: peak rate of pressure fall. Data are mean±SEM. Sham: sham group; MCT: monocrotaline 
group. *p < 0.05 vs. Sham of the same day; 
a
p < 0.05 vs. D14 of the same treatment group, 
b
p < 0.05 vs. D7 of the same treatment group; 
c
p < 0.05 vs. D3 of the same treatment group; 
d
p < 0.05 
vs. D1 of the same treatment group. 
  
Table 4. Morphometric progression of MCT-induced PAH. 
 D1 D3 D7 D14 D21 
 
Sham MCT Sham MCT Sham MCT Sham MCT Sham MCT 
Body weight (g) 194.1 ± 5.1 195.4 ± 5.9 211.0 ± 4.7
d
 198.6 ± 1.7 230.4 ± 8.2
c,d
 214.6 ± 3.2 262.2 ± 9.5
b,c,d
 253.7 ± 6.0
b,c,d
 290.6 ± 4.5
a,b,c,d
 260.8 ± 4.9*
,b,c,d
 
HW/BW (g/Kg) 3.271 ± 0.028 3.243 ± 0.091 3.242 ± 0.047 3.189 ± 0.059 3.031 ± 0.079 3.129 ± 0.061 2.862 ± 0.037
c,d
 3.025 ± 0.051 2.794 ± 0.069
c,d
 3.282 ± 0.113* 
RV/(LV+S) (g/g) 0.264 ± 0.014 0.265 ± 0.021 0.268 ± 0.013 0.260 ± 0.005 0.282 ± 0.017 0.332 ± 0.021 0.287 ± 0.018 0.320 ± 0.011 0.302 ± 0.012 0.467 ± 0.049*
,a,b,c,d
 
RV/BW (g/Kg) 0.578 ± 0.025 0.591 ± 0.040 0.578 ± 0.023 0.590 ± 0.016 0.583 ± 0.038 0.665 ± 0.036 0.560 ± 0.032 0.608 ± 0.021 0.584 ± 0.013 0.911 ± 0.095*
,a,b,c,d
 
(LV +S)/BW (g/Kg) 2.197 ± 0.037 2.240 ± 0.037 2.165 ± 0.030 2.274 ± 0.061 2.070 ± 0.058 2.011 ± 0.047
c,d
 1.956 ± 0.037
c,d
 1.900 ± 0.026
c,d
 1.957 ± 0.060
c,d
 1.956 ± 0.042
c,d
 
RV CSA (µm
2
) 131.2 ± 2.4  134.1 ± 1.9 128.2 ± 2.3 132.4 ± 2.2 139.6 ± 2.4 151.5 ± 2.6*
,c,d
 197.9 ± 5.2
b,c,d
 254.0 ± 6.0*
b,c,d
 169.5 ± 4.4
 a,b,c,d
 332.8 ± 10.0*
,a,b,c,d
 
L/BW (g/Kg) 5.731 ± 0.260 5.592 ± 0.117 5.426 ± 0.202 5.311 ± 0.140 5.436 ± 0.307 5.896 ± 0.400 4.661 ± 0.173 5.639 ± 0.220* 4.782 ± 0.323 7.241 ± 0.464*
,a,b,c,d
 
G/Tib (g/cm) 0.341 ± 0.008 0.337 ± 0.023 0.348 ± 0.008 0.345 ± 0.012 0.382 ± 0.012 0.374 ± 0.004 0.423 ± 0.020 0.416 ± 0.013 0.440 ± 0.016 0.430 ± 0.008 
 
 
 
HW/BW: heart weight/body weight; RV/(LV+S): right ventricle/(left ventricle+septum); RV/BW: right ventricle/body weight; (LV+S)/BW: (left ventricle+septum)/body weight; CSA: cross sectional area; L/BW: lung/body 
weight; G/Tib: gastrocnemius/tibia; Sham: sham group; MCT: monocrotaline group Data are mean±SEM. *p < 0.05 vs. Sham of the same day; 
a
p < 0.05 vs. D14 of the same treatment group, 
b
p < 0.05 vs. D7 of the same 
treatment group; 
c
p < 0.05 vs. D3 of the same treatment group; 
d
p < 0.05 vs. D1 of the same treatment group. 
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Normalized lung weight was significantly increased in MCT groups compared with Sham groups in days 14 
and 21. Also in MCT treated animals, at D21, the L/BW parameter was significantly higher when compared 
to the other time-points evaluated. As demonstrated in Figure 5. pulmonary arterial wall suffered a 
significant thickening  from day 14 and forward in MCT groups.  
 
 
 
 
A 
B 
Figure 5. Pulmonary arterial hypertrophy. A) Histological appearance of small pulmonary arteries stained with hematoxylin and eosin; B) 
Percentage of arterial medial layer hypertrophy. Sham: Sham group; MCT: monocrotaline group. Data are mean±SEM; *p < 0.05 vs. Sham of the 
same day, 
b
p < 0.05 vs. D7 of the same treatment group, 
c
p < 0.05 vs. D3 of the same treatment group, 
d
p < 0.05 vs. D1 of the same treatment 
group. 
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10.3. Survivin and Smac/DIABLO expression 
Lung survivin and Smac/DIABLO expression are shown in Figures 6, A and B. Survivin expression is 
augmented in MCT groups in days 7 and 21 when compared with Sham groups. Moreover, MCT groups 
presented a significant reduction from day 7 to day 21. No differences were noted between days in Sham 
groups. In contrast, pulmonary Smac/DIABLO expression decreases in MCT groups compared to Sham 
groups in both time-points.  
 
 
 
 
 
 
 
 
 
Figure 7. (A, B and C) shows survivin expression in the right ventricle. When in comparison with Sham 
group, MCT treated animals survivin expression is barely present on day 3 after injection and significantly 
rises on day 7, further increasing throughout days 14 and 21. Confirmation by western blotting (C) 
demonstrated a significantly increase in protein expression in MCT groups between day 7 and 21 after 
injection. Sham groups do not suffer any alteration between time points.  
Contrarily, MCT groups presented a lower Smac/DIABLO expression since D3 and forward when compared 
with Sham animals. (Figure 8. A, B and C) 
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Figure 6. Pulmonary survivin and Smac/DIABLO expression (A and B, respectively), evaluated by western blot. Sham: sham group, MCT: 
monocrotaline group. Data are mean±SEM. *p < 0.05 vs. Sham of the same day, 
b
p < 0.05 vs. D7 of the same treatment group. 
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Figure 7. Survivin expression in the right ventricle evaluated by immunohistochemistry (A and B) and by western blot (C) during the 
progression of pulmonary arterial hypertension. Sham: Sham group, MCT: monocrotaline group. Data are mean±SEM. *p < 0.05 vs. Sham of the 
same day, 
b
p < 0.05 vs. D7 of the same treatment group, 
d
p < 0.05 vs. D1 of the same treatment group. 
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RV Smac/DIABLO expression  
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Figure 8. Smac/DIABLO expression in the right ventricle evaluated by immunohistochemistry (A and B) and by western blot (C) during the 
progression of pulmonary arterial hypertension. Sham: Sham group, MCT: monocrotaline group. Data are mean±SEM. *p < 0.05 vs. Sham of the 
same day, 
d
p < 0.05 vs. D1 of the same treatment group. 
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11. Terameprocol in vivo study 
11.1. Regression of RV dysfunction in MCT animals treated with TMP 
Table 6. summarizes the results from bi-ventricular hemodynamic evaluation. In MCT+TMP animals, TMP 
treatment reverted the augmentation in RVPmax observed in MCT+Vehicle group (Figure 9. A). Inversely, 
CO was diminished in MCT+Vehicle animals and chronic TMP administration returned this parameter back 
to its normal condition (Figure 9. B). No alterations were noted in Sham groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Peak rates of RV pressure rise and fall as well as Ea and EF were increased in MCT groups treated with 
vehicle. In MCT+TMP animals the increase was significantly reduced. 
Diastolic function was markedly impaired in MCT+Vehicle group, namely there was an increase in end-
diastolic pressure and a longer RV time constant tau. TMP injections normalized both end-diastolic 
pressure and tau in MCT treated animals.  
Regarding the left ventricle assessment no significant alterations were registered. 
. 
 
 
 
 
Sham MCT
0
20
40
60
80
Vehicle
TMP

 
P
m
a
x
(m
m
H
g
)
Sham MCT
0
20
40
60
80

 
C
O
 (
m
L
/m
in
)
A B 
Figure 9. Terameprocol effects on RV maximal pressure and cardiac output (A and B, respectively). Sham: Sham group, MCT: 
monocrotaline group, TMP: Terameprocol, CO: cardiac output, Pmax: maximum pressure. Data are mean±SEM. 
α
p < 0.05 vs. Sham+V, 
β
p < 0.05 vs. 
Sham+TMP and 
γ
p <0.05 vs. MCT+V. 
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Table 5. Terameprocol effects on cardiac hemodynamics 
 
Sham  MCT 
 Vehicle TMP Vehicle TMP 
Heart rate (bpm) 
380.5 ± 8.402 376.5 ± 8.425 365.4 ± 5.608 386.1 ± 7.373 
RV Function 
o dP/dt max (mmHg/sec) 1500 ± 26.55 1627 ± 65.47 3450 ± 468.6
α β
 2107 ± 83.22
γ
 
o dP/dt min (mmHg/sec) -1485 ± 151.4 -1325 ± 18.62 -2903 ± 165.4
 α β
 -1763 ± 27.86
 β γ
 
o EF (%) 65.42 ± 5.536 70.04 ± 3.858 29.41 ± 4.383
 α β
 70.56 ± 4.902
 γ
 
o EDP (mmHg) 2.951 ± 0.1836 3.561 ± 0.4696 6.424 ± 1.137
 α β
 3.165 ± 0.6209
 γ
 
o Ea (mmHg/µL) 0.1528 ± 0.0115 0.1468 ± 0.0079 0.7701 ± 0.1588
 α β
 0.2661 ± 0.0372 
o Tau (ms) 10.84 ± 0.7640 10.43 ± 0.7636 15.96 ± 0.3210
 α β
 9.229 ± 0.7491
 γ
 
LV Function 
o Pmax (mmHg) 84.89 ± 5.706 94.14 ± 1.525 97.17 ± 4.977 94.66 ± 3.743 
o dP/dt max (mmHg/sec) 5582 ± 460.5 6517 ± 297.9 5724 ± 217.8 5518 ± 321.0 
o dP/dt min (mmHg/sec) -5180 ± 888.4 -6785 ± 430.0 -5242 ± 458.3 -6434 ± 380.8 
o EF (%) 73.82 ± 3.931 72.89 ± 4.410 71.47 ± 2.945 68.72 ± 3.969 
o EDP (mmHg) 5.427 ± 1.538 4.376 ± 1.272 4.531 ± 0.7069 6.576 ± 1.885 
o Ea (mmHg/µL) 0.4007 ± 0.076 0.4911 ± 0.0645 0.7408 ± 0.1039 0.7330 ± 0.1712 
o Tau (ms) 8.609 ± 0.3356 9.136 ± 0.8681 9.015 ± 0.5702 9.754 ± 0.6173 
 
 
 
 
11.2. Terameprocol reverts pulmonary and cardiovascular remodelling 
A lower body weight was observed in both MCT groups (Table 7.). MCT injection induced an increase in 
heart weight (HW) in MCT+V animals that was reverted with the injection of TMP as shown by HW/BW ratio 
(Table 7.). Moreover, MCT and TMP administration did not induced any alterations in LV morphometric 
parameters. Regarding Sham groups there were no differences in right or left ventricle parameters. 
 
 
 
 
 
Sham: Sham group, MCT: monocrotaline group. TMP: Terameprocol; Pmax: maximum pressure; dP/dtmax: peak rate of pressure rise; dP/dtmin: peak 
rate of pressure fall; EF: Ejection fraction; EDP: end-diastolic pressure; Ea: arterial elastance; Tau: time constant of ventricular decay. Data are 
mean±SEM. 
α
p < 0.05 vs. Sham+V, 
β
p < 0.05 vs. Sham+TMP and 
γ
p<0.05 vs. MCT+V. 
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Table 6. Effects of Terameprocol in morphometric characteristics. 
 
Sham MCT 
 
Vehicle TMP Vehicle TMP 
Body weight (g) 300.1 ± 8.2 268.6 ± 11.4 258.6 ± 5.6
α
 249.7 ± 8.0
α
 
HW/BW (g/Kg) 3.013 ± 0.103 2.734 ± 0.096 3.634 ± 0.317
α,β
 3.068 ± 0.176
γ
 
RV/(LV+S) (g/g) 0.3043 ± 0.0109 0.3401 ± 0.0299 0.4589 ± 0.0362
α,β
 0.3685 ± 0.0189
γ
 
(LV+S) /BW (g/Kg) 1.856 ± 0.052 1.771 ± 0.063 2.035 ± 0.081 1.837 ± 0.044 
G/Tib (g/cm) 0.5200 ± 0.0147 0.4857 ± 0.0092 0.4951 ± 0.0138 0.4290 ± 0.0177 
 
 
MCT induced RV hypertrophy in MCT animals injected with vehicle which was reverted by TMP as shown 
by RV/BW (Figure 10. A). This result was confirmed by histology where MCT administration induced 
hypertrophy at cardiomyocyte level. MCT+TMP exhibited significant less hypertrophy when compared with 
the other MCT animals (Figure 10. B). 
 
 
 
 
 
 
 
 
 
 
 
Sham MCT
0.0
0.5
1.0
1.5

 
Vehicle
TMP
R
V
/B
W
 (
g
/K
g
)
HW/BW: heart weight/body weight; RV/(LV+S): right ventricle/(left ventricle+septum); (LV+S)/BW: (left ventricle+Septum)/body weight; G/Tib: 
gastrocnemius/tibia. Sham: sham group; MCT: monocrotaline group; TMP: Terameprocol. Data are mean±SEM. 
α
p < 0.05 vs. Sham+Vehicle; 
β
p < 
0.05 vs. Sham+TMP, 
γ
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Figure 10. Terameprocol effects on the right ventricle structure demonstrated by right ventricle/body weight ratio (RV/BW) and cardiomyocyte 
cross sectional area (CSA) (A and B respectively). Sham: Sham group, MCT: monocrotaline group, TMP: Terameprocol. Data are mean±SEM. 
α
p < 
0.05 vs. Sham+V, 
β
p < 0.05 vs. Sham+TMP and 
γ
p<0.05 vs. MCT+V. 
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Regarding lung weight this was significantly increased in MCT+Vehicle as demonstrated by L/BW ratio. 
TMP injection reverted this parameter as well as attenuated the medial hypertrophy of the lung small caliber 
arteries when compared with MCT+Vehicle (Figure 11. A and C). No significant differences were noted in 
Sham groups. 
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Figure 11. Pulmonary response to Terameprocol evaluated by lung weight/body weight ratio (L/BW) and by the percentage of medial 
hypertrophy of pulmonary arteries (B, A and C respectively). Sham: Sham group, MCT: monocrotaline group, TMP: Terameprocol. Data are 
mean±SEM. 
α
p < 0.05 vs. Sham+V, 
β
p < 0.05 vs. Sham+TMP and 
γ
p<0.05 vs. MCT+V. 
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PAH is a multifactorial disorder that commonly leads to right heart failure and death. Throughout the years, 
research has been focusing on the rat model of MCT-induced PAH to better understand the disease as well 
as different therapeutic options. Even though alterations like plexiform lesions (typical in human disease) 
are not mimicked by this model, MCT induces pulmonary vascular remodeling and RV hypertrophy, both 
aims of our progression study. Moreover, most studies reflect the advanced stages of this pathology (D25-
35 after MCT injection) probably because nearly all patients with PAH present with late-stage disease. To 
our knowledge studies on the early features of PAH are essential to better understand its development and 
pathophysiologic pathways. Current therapeutic options specifically focus on vasodilators, though with a 
very limited impact in the overall outcome of the patient. Therefore, research is pursuing strategies to 
reverse the remodeling of the pulmonary vasculatures by interfering with the disturbed balance between cell 
apoptosis and proliferation151, 152. In the present study we investigated the natural progression of MCT-
induced PAH and identified the timing of appearance of its hemodynamic and morphological features 
correlated with apoptosis proteins: survivin and Smac/DIABLO expression. After establishing these proteins 
patterns we modulated it through chronic in vivo administration of terameprocol. 
Survivin, an anti-apoptotic protein, has been reported to be significantly increased to aberrantly promote cell 
survival in neoplasia of various cancers111, 153 being of interest also in PAH for the same reasons. In PAH, 
cardiac hypertrophy allows RV to endure the pressure overload in a compensatory response. The exact 
role of apoptosis and specially survivin in cardiovascular physiology and diseases still requires more 
research. Some groups demonstrated the cardioprotective increased expression of survivin in myocardial 
injury inversely correlated with apoptosis154-156. In fact, a study in a model of spontaneously hypertensive 
rats discovered that myocardial expression of survivin in ageing and HF is inversely correlated with cardiac 
apoptosis and associated with a more favorable cardiac remodeling156. Levkau and collegues157 also 
suggest a role of survivin in cardiac by showing it to be essential for the regulation of cardiomyocyte 
proliferation and mitosis. In fact, knockouts for survivin gene presented an inverse correlation between 
cardiomyocyte polyploidy and cardiomyocyte number leading to progressive HF and death. The same study 
demonstrated that survivin overexpression in cultured rat neonatal cardiomyocytes promoted cell division to 
protect those cells against apoptosis. Finally, Levkau established that only very low levels of survivin were 
present in normal human heart whereas patients with terminal HF showed increased levels of this anti-
apoptotic protein. In the same patients, the expression of survivin was reverted after hemodynamic support 
through left ventricle assisting device (LVAD) raising the possibility that cardiac survivin expression is load-
dependent. Supporting Levkau’s hypothesis, in our study we demonstrated that survivin expression was 
progressively increased throughout the development of MCT-induced PAH. The first incidence of survivin 
augmentation was 7 days after MCT injection, the time point where RV cardiomyocyte hypertrophy is first 
present and where no hemodynamic dysfunction was noticed. Interestingly, RV hemodynamic alterations 
were only observed 14 days after MCT administration. Moreover, McMurtry and colleagues also 
demonstrated that lung survivin overexpression preceded hemodynamic alterations verified in the disease, 
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which is comprehensible since pulmonary arterial remodeling is the most important pathogenic mechanism 
of MCT-induced PAH. These correlations together with our results make us believe that pulmonary vascular 
remodeling leads probably to a neurohumoral signaling to the RV inducing survivin overexpression and 
cardiomyocyte hypertrophy. Some of the molecules that might be responsible for survivin upregulation in 
the RV are ET-1, angiotensin-II, catecholamines and PDGF51. In fact, a positive feedback relationship 
among PDGF and survivin has been demonstrated to induced SMCs proliferation and apoptosis resistance 
in arterial injury models103, 158. In the future, more studies on the molecular survivin signalling in PAH are 
needed in order to better understand and comprove this neurohumoral pathway. 
The pro-apototic actions of the protein Smac/DIABLO occur from its interaction with IAP proteins preventing 
their inhibitory effect on caspases122, 159, 160. On the other hand, excessive survivin retains Smac/DIABLO in 
the mitochondria, inhibiting its pro-apoptotic activity123, 161. Comparing with RV survivin expression, our 
molecular and histological results show an inverse pattern of Smac/DIABLO, as it progressively decreases 
throughout the development of PAH. Thus we suggest that an equilibrium between survivin and 
Smac/DIABLO could be essential for cardiomyocyte fate in response to apoptotic stimuli. In support of our 
hypothesis, other groups also demonstrated an antagonism between survivin and Smac/DIABLO in 
different types of cancers162-166.  
Although current vasodilation therapies for PAH improve quality of life and survival of patients167-169, they 
don’t halt the progression of the disease and therefore there is no cure for PAH available until now170, 171. 
Research is now pursuing strategies that could reverse structural remodelling in the pulmonary arterial bed, 
thus providing a more significant decrease in pulmonary vascular resistance151, 152, 172. The 
hyperproliferative and apoptosis-resistant phenotype of PASMCs in PAH constitutes a striking therapeutic 
target. In cancer, several anti-survivin therapies have been tested, being some of them already in clinical 
trials. For instance, McMurtry173 demonstrated that delivery gene therapy to inhibit survivin reverted MCT-
induced PAH and improved survival. This protein inhibition led to a decrease in proliferation and induced 
apoptosis of PASMCs without causing systemic alterations173. However, pharmacological modulation of 
survivin in PAH, if similarly effective, would probably be more promptly translated into clinical care than 
gene therapy. In this context, TMP, an anti-survivin drug, was proven to inhibit proliferation and stimulate 
apoptosis both in vitro and in vivo without causing systemic toxicity.  Our data demonstrate that modulation 
of survivin pathway through chronic administration of TMP can be effective on attenuating the pulmonary 
vascular remodelling with a decrease in the pulmonary artery medial hypertrophy. Interestingly, for the first 
time, we were able to describe that TMP administration resulted in a fully reversion of RV hypertrophy as 
well as both systolic and diastolic RV hemodynamic dysfunction. Since no LV alterations were observed, all 
of these data from the in vivo study also support our neurohumoral hypothesis. Finally, in conformity with 
previous research we also did not registered any systemic alterations when administrating TMP.  
Given the lack of therapies aiming remodelling in PAH, our results lead us to believe that TMP would be an 
interesting pharmacological approach to the treatment of this disease.
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In the present study it was evaluated the involvement of apoptosis in the pathogenesis of PAH through the 
expression and modulation of the anti-apoptotic protein survivin. Our data clearly shows survivin 
overexpression both at cardiac and pulmonary levels of disease animals. Interestingly, the increase in 
survivin cardiomyocyte expression (and decreasing of the antagonist Smac/DIABLO) was correlated with 
the beginning of cardiomyocyte hypertrophy. Moreover, both pulmonary and RV survivin overexpression 
preceded hemodynamic alterations in the RV. This suggests that the deregulation in the balance between 
apoptosis and survival can be load-independent and due to a compensatory neurohumoral response. 
Additionally, anti-survivin agent TMP specifically reverted pulmonary and RV remodeling by decreasing 
both pulmonary medial and cardiomyocyte hypertrophy. The same drug also normalized hemodynamic RV 
alterations noticed in the disease group. These in vivo results demonstrate that TMP may be a potential 
therapeutic option to PAH. 
As future research, we intend to evaluate what type of neurohumoral stimuli is leading to survivin 
overexpression in PAH. Also relevant would be to understand the specific actions of this protein in PAH by 
studying its expression in cytoplasmic, nuclear and mitochondrial cellular fractions. Finally, because little is 
known about the role of survivin in the heart it would be interesting, has future research, to evaluate survivin 
expression/actions in isolated adult cardiomyocytes of PAH animals. 
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